Lori Brisbin is a molecular biologist who leads Texas Oncology’s Precision Medicine program. She is responsible for maximizing the use of precision medicine within Texas Oncology, with a focus on data capture and utilization for research, as well as collaboration with pharmaceutical partners for clinical trials matching and data aggregation.
Ms. Brisbin previously served as chief commercial officer for Medfusion, where she lead an expansion of the molecular oncology program, and helped implement genetic test data capture capabilities for Texas Oncology and Rocky Mountain Cancer Centers. She previously worked at Roche Molecular Systems, QIAGEN, and Novartis where she helped develop molecular genetic solutions for oncology and infectious disease.
Lori Brisbin earned a Master of Science degree in molecular biology from Syracuse University in Syracuse, New York.
Joel Diamond, MD, FAAFP, has extensive clinical and technology experience. He formerly served as CMIO and chairman of the Physician Advisory Board at the UPMC/St. Margaret Memorial Hospital, where he facilitated 100% adoption of CPOE. He helped develop dbMotion, a solution for health information exchange and population health and later became the Chief Medical Officer for Population Health at Allscripts Healthcare. Dr. Diamond is a diplomat of the American Board of Family Practice and a fellow in the American Academy of Family Physicians, while continuing to care for patients at Handelsman Family Practice in Pittsburgh, PA, and serving as the CMO for 2bPrecise.
Dr. Dickson is a practicing medical oncologist with deep experience in clinical trial reporting, molecular medicine and data collection. He previously served as CEO of the Summarius Corporation, which developed a proprietary format for clinical trial reporting and was adopted by two pharmaceutical companies. He was also a scientific advisor for two Medicare Administrative Contractors, advising on technical merits and evidence strength of molecular testing. In addition, he served as the Director of Clinical Science at Palmetto GBA’s MolDX program where he worked with many stakeholders on the technical and clinical strength of molecular medicine testing and direction.
Currently, he is CEO and founder of Taproot Health, which uses novel scientific approaches and business models to collect clinico-panomic data needed to advance precision medicine. He is the Director of Precision Medicine Policy and Registries at the Knight Cancer Center at Oregon Health and Science University. He has also served in various service and leadership roles in the Idaho Society of Clinical Oncology (ISCO) and the American Society of Clinical Oncology (ASCO).
From 2013-2018, Dr. Dressler developed and implemented the first Personalized Medicine and Pharmacogenomics Program (PMP) at Mission Health, a rural community health system in western North Carolina. Formerly a faculty member in the Schools of Medicine and Pharmacy at the University of North Carolina at Chapel Hill, and a founding member of the UNC Institute for Pharmacogenomics and Individualized Therapy, Dressler’s 35+ year career spans translational laboratory research in cancer, health policy research and the ethical ,legal, and social implications (ELSI) of genomic medicine At UNC, her laboratory conducted the research study that directly led to the FDA approval of the HER2 FISH assay (PathVYsion ™), one of the first pharmacogenomic tests in solid tumors. At Mission, Dressler has implemented a clinical and research program in Personalized Medicine for cancer and non-cancer patients. In cancer patients, the program helps to meet/exceed national guidelines for tumor marker testing to predict response to drugs for targeted and immunotherapy approaches. In non-cancer patients, the program has implemented education, training, and clinical decision support for FDA designated black box drugs and conducted several demonstration projects bringing pharmacogenetics to primary care and specialty practices. In North Carolina, nearly 10 years prior to GINA, (Genetic Information Non Discrimination Act, Federal Statute), Dressler worked with the North Carolina General Assembly to pass a law to prohibit discrimination by employers and health insurance providers on the basis of an individual’s genetic information. She has consulted with NIH, NCI, NHGRI and NAM and has over 100 publications in related fields.
Vice President and Senior Medical Director, Cardinal Health Specialty Solutions
Ajeet Gajra, MD, MBBS, FACP serves as Vice President and Senior Medical Director for Cardinal Health Specialty Solutions. In his capacity at Cardinal Health, Dr. Gajra serves all divisions of Specialty Solutions to provide business strategy and counsel, as well as clinical subject matter expertise on evolving healthcare policy and the biopharma manufacturer industry. He provides directional leadership to multiple units with a special focus on regulatory sciences and real-world evidence research to build a robust culture of research, including real-world evidence, health economics, and patient-reported outcomes-based research.
A nationally recognized expert in lung cancer and geriatric oncology, Dr. Gajra is an ABIM board-certified medical oncologist/hematologist, with more than 16 years of clinical experience managing all types of cancer and blood disorders. His clinical experience includes serving as Associate Director of the Upstate Cancer Center, where he provided leadership and oversight of clinical operations as well as quality programs. He also previously served as Medical Director for the center, managing a team of oncologists, APPs and navigators, as well as multiple practice sites with infusion centers, and leading several value-based care initiatives, including OCM and ASCO-QOPI programs.
In addition to his clinical experience, Dr. Gajra has served on the medical faculty at SUNY Upstate Medical University as a professor of medicine and program director for hematology/oncology fellowships.
His research experience includes serving as Medical Director for Medical Affairs Oncology at ICON research, a global full-service CRO, where he led design, oversight, clinical development and regulatory interactions for phase I-IV trials in oncology and hematology including immuno-oncology, adoptive cell therapy and CAR-T cell therapy. Prior to that he has served as the Principal Investigator for more than 40 clinical trials including pharmaceutical sponsored, US cooperative group and investigator initiated studies.
Dr. Gajra has published more than 100 peer-reviewed manuscripts in publications such as Journal of Clinical Oncology, Cancer, Lancet Oncology and Blood. He has co-authored or presented more than 150 abstracts at notable scientific meetings, including ASCO, the American Society of Hematology (ASH) and the American Association for Cancer Research (AACR). He was named an FACP fellow in 2011 and has also served on the lung cancer guidelines committee of ASCO.
He received his MBBS and MD (Internal Medicine) from Delhi University in New Delhi, India and completed his residency at SUNY Upstate Medical University, where he also completed his fellowship medical oncology and hematology.
A specialist in cancer signal transduction pathways, Liat Goldberg, PhD, earned her doctorate in neurobiology from Tel-Aviv University. Her career has focused on in cancer research, from basic science to pre-clinical and clinical data interpretation for both solid tumors and hematopoietic malignancies. Currently lead scientist for 2bPrecise, Dr. Goldberg’s likewise displays deep expertise in bioinformatics analysis of NGS datasets, as well as gene expression arrays and chromatin immunoprecipitation sequencing, variant analysis, and interpretation for both inherited disorders and cancer. Following post-doctoral work with the Cancer Research Center at the Sheba Medical Center in Israel and the National Cancer Institute in the U.S., Dr. Goldberg served as a review analyst for GeneDx in Maryland and Head of Molecular Analysis for GeneSort in Israel.
James Hamrick, MD, MPH is a Senior Medical Director at Flatiron Health, and a board certified physician in Medical Oncology, Hematology and Internal Medicine. In his role at Flatiron, he provides clinical management expertise across the range of blood and cancer diseases, in addition to a physician’s perspective and represents patients’ viewpoints for our products’ development. James has a clinical practice at Kaiser Permanente Georgia.
Director, Institute for Precision Medicine, Pittsburgh Foundation Chair, University of Pittsburgh
Dr. Adrian Lee is the Pittsburgh Foundation Chair and Director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalized well-being and clinical care. He is also Professor of Pharmacology & Chemical Biology and Human Genetics at UPMC Hillman Cancer Center.
Dr. Lee received B.Sc. and Ph.D. degrees in England, and came to San Antonio, Texas for his postdoctoral studies. He was subsequently recruited to Baylor College of Medicine and to the University of Pittsburgh in 2010.
Since his recruitment to the University of Pittsburgh in 2010, Dr. Lee has had a key role in shaping precision medicine research at the University of Pittsburgh and personalized care at UPMC. An example of the early progress in precision medicine at Pitt and UPMC is research and implementation of pharmacogenomics, and development of computational systems and architecture for sharing of clinical and genomic data both at the University of Pittsburgh and in the UPMC healthcare system. In cancer, efforts are underway to enhance genomic testing and use of targeted therapies.
The goal of Dr. Lee’s laboratory is to translate basic cell and molecular research findings into the understanding and treatment of breast cancer. Dr. Lee has examined the effect of intratumor heterogeneity on prognostic tests in breast cancer, and is currently leading an effort to sequencing metastatic breast cancers to identify vulnerabilities for novel precision therapies. Dr Lee has published over 180 peer reviewed research articles. His laboratory is supported by funding from the NIH, Department of Defense, Susan G. Komen for the Cure, Breast Cancer Research Foundation, and other sources. Dr. Lee serves on numerous national peer-review committees and is on the Editorial Board of several journals. In 2018 Dr. Lee was awarded the Terri L Chapman award from Susan G. Komen, the PNC Elsie Hillman Distinguished Scholar award, and the University of Pittsburgh Biomedical Graduate Scholar Association (BGSA) Distinguished Mentor Award.
Dr Messino is Founder of Messino Cancer Centers (MCC), a team of 14 medical oncologists and 18 physician assistants and nurse practitioners who provide a comprehensive range of treatment for adult patients diagnosed with cancer and blood disorders in Western North Carolina. MCC is dedicated to providing the most advanced and innovative treatments of the highest quality. MCC provide state-of-the-art evidence-based medicine for patients, incorporating personalized medicine, standard and nationally accepted guidelines, and clinical trials. Through care management and dedicated oncology certified staff, MCC provide support for patients through all phases of their diagnosis and treatment. Care is provided with the utmost concern and consideration of what is best for the whole person throughout their cancer journey. The physicians of MCC are grounded in the region of Western North Carolina and devoted to providing care to patients in their communities.
Dr. Messino is board certified in internal medicine and medical oncology, completed a fellowship in bone marrow transplant and previously served as Mission Hospital’s Head of Oncology. Dr. Messino is known throughout the region for the kindness and care he provides to patients, the support and loyalty he has for his colleagues and the community, and the value he places in the oncology staff who devote their expertise, kindness and time to caring for patients. He has spent countless hours with patients, doing whatever it takes to ensure that they receive the best treatment possible. His years of experience have provided him a unique ability to manage complex cases in medical oncology.
Recently, Dr. Messino received the prestigious governor’s award in North Carolina for his outstanding quality care. “Dr. Messino is a visionary who 30 years ago recognized the need for expert and nearby cancer care,” said AON CEO Brad Prechtl, MBA. “We applaud him for this well-deserved recognition and his commitment to building the highest quality cancer center in Asheville and in rural areas that were underserved.”
Rebecca Owens is a healthcare executive who has worked with oncologists and pathologists to advance precision medicine over the past 18 years. Rebecca passionately believes that cancer care will advance more rapidly when the industry can streamline and link quality diagnostic data and well-defined patient clinical data together. Rebecca focuses on closing the gaps, by use of novel approaches, between disparate data sources. Rebecca is the Co-Founder and Chief Commercial Officer of Taproot Health. Taproot Health is a novel approach to bringing biomarker testing and clinical outcome data together within a physician-centric business model. Rebecca focuses her talent on business strategy, fundraising, marketing and operational efficiencies. Through Taproot Health Rebecca hopes to demonstrate that bringing complex data together requires an “all hands on deck” approach. Leading up to Taproot Health, Rebecca helped to establish the CureOne N1 Registry, a non-profit patient registry. As the Chief Commercial Officer she had many organizational responsibilities. One accomplishment Rebecca is most proud of achieving is the Medicare status as a Quality Clinical Data Registry (QCDR) for physician quality metric reporting. This designation established CureOne as a patient registry that met criterion for very discrete data element reporting, well-defined security parameters and physician reporting capabilities.
Medical Director, West Cancer Center, Chief of Division of Hematology/Oncology, University of Tennessee Health Science Center
Dr. Schwartzberg is the Chief Medical Director of West Cancer Center and Chief of the Division of Hematology/Oncology at the University of Tennessee Health Science Center. Dr. Schwartzberg was appointed by the new partnership, OneOncology, to Chief Medical Officer. He will remain the Medical Director and actively see patients at West Cancer Center. In addition, he also serves as the President and Chief Medical Officer for Vector Oncology, an oncology specific SMO/CRO. A renowned expert in the study and treatment of breast cancer, precision medicine and supportive care, Dr. Schwartzberg is a member of the Board of Directors for the National Comprehensive Cancer Network and is the founding editor-in-chief of the journal Community Oncology. The author of more than 180 research publications, he is also the current editor-in-chief of the Practice Update Oncology website and serves on the editorial board for both the Journal of Supportive Oncology and the ASCO Post. Dr. Schwartzberg left Memorial Sloan-Kettering Cancer Center in 19…to join Dr. William H. West and Dr. Kurt Tauer as one of the original founding partners of West Clinic-now West Cancer Center.
Jill Tapper has more than 15 years’ experience directing operations and defining business strategy for clinical genetics & genomics services, laboratories and programs. Holding a master’s degree in Healthcare Administration, a bachelor’s degree in Health Science and ASCP certification as a Specialist in Cytogenetics, Jill is also an accomplished clinical technologist who has multiple peer-reviewed publications in the areas of clinical genetics, cytogenetics and molecular diagnostics. Jill served as the Administrator of Human & Molecular Genetics Center at the Medical College of Wisconsin (MCW), where she was part of the team that was among the first to use genomic sequencing to render a patient diagnosis that subsequently led to a lifesaving treatment for a young boy. Her expertise in the financial, business, and management aspects of the clinical laboratory industry, coupled with her technical knowledge were instrumental in the successful development and operationalization of the Clinical Sequencing Laboratory in the HMGC at MCW. In 2015 she and her MCW colleagues founded Envision Genomics, a company focused on unlocking the value of the genomic sequence to diagnose and guide the care of patients with rare disease and other complex medical conditions.
Clinical Assistant Professor, School of Medicine, Department of Hematology & Oncology, eRecord Medical Director for Oncology, University of Pittsburgh Hillman Cancer Center
Roby A. Thomas, MD, is a medical oncologist and hematologist at UPMC Hillman Cancer Center. Dr. Thomas is trained in the management of all cancers and blood disorders with a focus in genitourinary malignancies, gastrointestinal malignancies, and benign hematology.
Dr. Thomas is board-certified in internal medicine, medical oncology and hematology. Dr. Thomas has a background in chemical engineering from the University of Virginia in Charlottesville, followed by work as a consultant in information technology at IBM. He changed careers to medicine and received his medical degree from the American University of the Caribbean in St. Maarten. Dr. Thomas completed a residency at West Virginia University in internal medicine, followed by a fellowship at the University of Pittsburgh, serving as the chief fellow in his final year.
His research interests include precision medicine and working with researchers from Carnegie Mellon University in the development and use of machine learning and artificial intelligence to better understand cancer.
Dr. Thomas is a member of the American Medical Association, American Society of Hematology, and American Society of Clinical Oncology.